Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 29;4(4):CD012191.
doi: 10.1002/14651858.CD012191.pub2.

Risk-reducing medications for primary breast cancer: a network meta-analysis

Simone Mocellin  1 , Annabel Goodwin, Sandro Pasquali
Affiliations

Risk-reducing medications for primary breast cancer: a network meta-analysis

Simone Mocellin et al. Cochrane Database Syst Rev. .

Abstract

Background: Breast cancer is the most frequently occurring malignancy and the second cause of death for cancer in women. Cancer prevention agents (CPAs) are a promising approach to reduce the burden of breast cancer. Currently, two main types of CPAs are available: selective estrogen receptor modulators (SERMs, such as tamoxifen and raloxifene) and aromatase inhibitors (AIs, such as exemestane and anastrozole).

Objectives: To assess the efficacy and acceptability of single CPAs for the prevention of primary breast cancer, in unaffected women, at an above-average risk of developing breast cancer.Using a network meta-analysis, to rank single CPAs, based on their efficacy and acceptability (an endpoint that is defined as the inverse of CPA-related toxicity).

Search methods: We searched the Cochrane Breast Cancer Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP), and ClinicalTrials.gov on 17 August 2018. We handsearched reference lists to identify additional relevant studies.

Selection criteria: We included randomized controlled trials (RCTs) that enrolled women without a personal history of breast cancer but with an above-average risk of developing a tumor. Women had to be treated with a CPA and followed up to record the occurrence of breast cancer and adverse events.

Data collection and analysis: Two review authors independently extracted data and conducted risk of bias assessments of the included studies, and assessed the certainty of the evidence using GRADE. Outcome data included incidence of breast carcinoma (both invasive and in situ carcinoma) and adverse events (both overall and severe toxicity). We performed a conventional meta-analysis (for direct comparisons of a single CPA with placebo or a different CPA) and network meta-analysis (for indirect comparisons).

Main results: We included six studies enrolling 50,927 women randomized to receive one CPA (SERMs: tamoxifen or raloxifene, or AIs: exemestane or anastrozole) or placebo. Three studies compared tamoxifen and placebo, two studies compared AIs (exemestane or anastrozole) versus placebo, and one study compared tamoxifen versus raloxifene. The risk of bias was low for all RCTs.For the tamoxifen versus placebo comparison, tamoxifen likely resulted in a lower risk of developing breast cancer compared to placebo (risk ratio (RR) 0.68, 95% confidence interval (CI) 0.62 to 0.76; 3 studies, 22,832 women; moderate-certainty evidence). In terms of adverse events, tamoxifen likely increased the risk of severe toxicity compared to placebo (RR 1.28, 95% CI 1.12 to 1.47; 2 studies, 20,361 women; moderate-certainty evidence). In particular, women randomized to receive tamoxifen experienced a higher incidence of both endometrial carcinoma (RR 2.26, 95% CI 1.52 to 3.38; high-certainty evidence) and thromboembolism (RR 2.10, 95% CI 1.14 to 3.89; high-certainty evidence) compared to women who received placebo.For the AIs versus placebo comparison, AIs (exemestane or anastrozole) reduced the risk of breast cancer by 53% (RR 0.47, 95% CI 0.35 to 0.63; 2 studies, 8424 women; high-certainty evidence). In terms of adverse events, AIs increased the risk of severe toxicity by 18% (RR 1.18, 95% CI 1.09 to 1.28; 2 studies, 8352 women; high-certainty evidence). These differences were sustained especially by endocrine (e.g. hot flashes), gastrointestinal (e.g. diarrhea), and musculoskeletal (e.g. arthralgia) adverse events, while there were no differences in endometrial cancer or thromboembolism rates between AIs and placebo.For the tamoxifen versus raloxifene comparison, raloxifene probably performed worse than tamoxifen in terms of breast cancer incidence reduction (RR 1.25, 95% CI 1.09 to 1.43; 1 study, 19,490 women; moderate-certainty evidence), but its use was associated with lower toxicity rates (RR 0.87, 95% CI 0.80 to 0.95; 1 study, 19,490 women; moderate-certainty evidence), particularly relating to incidence of endometrial cancer and thromboembolism.An indirect comparison of treatment effects allowed us to compare the SERMs and AIs in this review. In terms of efficacy, AIs (exemestane or anastrozole) may have reduced breast cancer incidence slightly compared to tamoxifen (RR 0.67, 95% CI 0.46 to 0.98; 5 RCTs, 31,256 women); however, the certainty of evidence was low. A lack of model convergence did not allow us to analyze toxicity data.

Authors' conclusions: For women with an above-average risk of developing breast cancer, CPAs can reduce the incidence of this disease. AIs appear to be more effective than SERMs (tamoxifen) in reducing the risk of developing breast cancer. AIs are not associated with an increased risk of endometrial cancer and thromboembolic events. However, long-term data on toxicities from tamoxifen are available while the follow-up toxicity data on unaffected women taking AIs is relatively short. Additional data from direct comparisons are needed to fully address the issues of breast cancer prevention by risk-reducing medications, with special regards to acceptability (i.e. the benefit/harm ratio).

PubMed Disclaimer

Conflict of interest statement

SM: none. AG: no competing interest associated with funding of travel to attend a national and international educational meeting or to provide expertise regarding Cancer Genetic counselling in Australia. SP: none.

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
3
3
Network plot: the figure represents the available direct comparisons among breast cancer risk‐reducing agents. Each study is represented by a black line. SERM: selective estrogen receptor modulator.
1.1
1.1. Analysis
Comparison 1 Tamoxifen versus placebo, Outcome 1 Overall breast cancer incidence.
1.2
1.2. Analysis
Comparison 1 Tamoxifen versus placebo, Outcome 2 Severe toxicity.
1.3
1.3. Analysis
Comparison 1 Tamoxifen versus placebo, Outcome 3 Invasive breast cancer incidence.
2.1
2.1. Analysis
Comparison 2 Aromatase inhibitors (AI) versus placebo, Outcome 1 Overall breast cancer incidence.
2.2
2.2. Analysis
Comparison 2 Aromatase inhibitors (AI) versus placebo, Outcome 2 Severe toxicity.
2.3
2.3. Analysis
Comparison 2 Aromatase inhibitors (AI) versus placebo, Outcome 3 Invasive breast cancer incidence.
2.4
2.4. Analysis
Comparison 2 Aromatase inhibitors (AI) versus placebo, Outcome 4 Overall toxicity.
3.1
3.1. Analysis
Comparison 3 Tamoxifen versus raloxifene, Outcome 1 Overall breast cancer incidence.
3.2
3.2. Analysis
Comparison 3 Tamoxifen versus raloxifene, Outcome 2 Severe toxicity.
3.3
3.3. Analysis
Comparison 3 Tamoxifen versus raloxifene, Outcome 3 Invasive breast cancer incidence.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD012191

References

References to studies included in this review

Cuzick 2014 {published data only}
    1. Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, et al. Anastrozole for prevention of breast cancer in high‐risk postmenopausal women (IBIS‐II): an international, double‐blind, randomised placebo‐controlled trial. Lancet 2014;383(9922):1041‐8. - PubMed
Cuzick 2015 {published data only}
    1. Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, et al. Tamoxifen for prevention of breast cancer: extended long‐term follow‐up of the IBIS‐I breast cancer prevention trial. Lancet Oncology 2015;16(1):67‐75. - PMC - PubMed
Fisher 2005 {published data only}
    1. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P‐1 study. Journal of the National Cancer Institute 2005;97(22):1652‐62. - PubMed
Goss 2011 {published data only}
    1. Goss PE, Ingle JN, Alés‐Martínez JE, Cheung AM, Chlebowski RT, Wactawski‐Wende J, et al. Exemestane for breast‐cancer prevention in postmenopausal women. New England Journal of Medicine 2011;364:2381‐91. - PubMed
Powles 2007 {published data only}
    1. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty‐year follow‐up of the Royal Marsden randomized, double‐blinded tamoxifen breast cancer prevention trial. Journal of the National Cancer Institute 2007;99(4):283‐90. - PubMed
Vogel 2010 {published data only}
    1. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P‐2 Trial: Preventing breast cancer. Cancer Prevention Research 2010;3(6):696‐706. - PMC - PubMed

References to studies excluded from this review

ALLHAT 2002 {published data only}
    1. ALLHAT Trial Investigators. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT‐LLT). JAMA 2002;288(23):2998‐3007. - PubMed
Archer 2009 {published data only}
    1. Archer DF, Pinkerton JV, Utian WH, Menegoci JC, Villiers TJ, Yuen CK, et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 2009;16(6):1109‐15. - PubMed
Avenell 2012 {published data only}
    1. Avenell A, MacLennan GS, Jenkinson DJ, McPherson GC, McDonald AM, Pant PR, et al. Long‐term follow‐up for mortality and cancer in a randomized placebo‐controlled trial of vitamin D(3)and/or calcium (RECORD trial). Journal of Clinical Endocrinology and Metabolism 2012;97(2):614‐22. - PubMed
Barrett‐Connor 2006 {published data only}
    1. Barrett‐Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. New England Journal of Medicine 2006;355(2):125‐37. - PubMed
Bolland 2011 {published data only}
    1. Bolland MJ, Grey A, Gamble GD, Reid IR. Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited‐access data set. American Journal of Clinical Nutrition 2011;94(4):1144‐9. - PMC - PubMed
Chlebowski 2008 {published data only}
    1. Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski‐Wend J, Rohan T, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. Journal of the National Cancer Institute 2008;100(22):1581‐91. - PMC - PubMed
Cook 2013 {published data only}
    1. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate‐day, low‐dose aspirin and cancer risk: long‐term observational follow‐up of a randomized trial. Annals of Internal Medicine 2013;159(2):77‐85. - PMC - PubMed
Cummings 2008 {published data only}
    1. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, et al. The effects of tibolone in older postmenopausal women. New England Journal of Medicine 2008;359(7):697‐708. - PMC - PubMed
Cuzick 2002 {published data only}
    1. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, et al. First results from the International Breast Cancer Intervention Study (IBIS‐I): a randomised prevention trial. Lancet 2002;360(9336):817‐24. - PubMed
DeCensi 2009 {published data only}
    1. DeCensi A, Robertson C, Guerrieri‐Gonzaga A, Serrano D, Cazzaniga M, Mora S, et al. Randomized double‐blind 2 x 2 trial of low‐dose tamoxifen and fenretinide for breast cancer prevention in high‐risk premenopausal women. Journal of Clinical Oncology 2009;27(23):3749‐56. - PMC - PubMed
DeCensi 2013 {published data only}
    1. DeCensi A, Bonanni B, Maisonneuve P, Serrano D, Omodei U, Varricchio C, et al. A phase‐III prevention trial of low‐dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study. Annals of Oncology 2013;24(11):2753‐60. - PubMed
Downs 1998 {published data only}
    1. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279(20):1615‐22. - PubMed
Erdmann 2014 {published data only}
    1. Erdmann E, Song E, Spanheimer R, Troostenburg de Bruyn AR, Perez A. Observational follow‐up of the PROactive study: a 6‐year update. Diabetes, Obesity and Metabolism 2014;16(1):63‐74. - PubMed
Fisher 1998 {published data only}
    1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P‐1 study. Journal of the National Cancer Institute 1998;90(18):1371‐88. - PubMed
Grady 2008 {published data only}
    1. Grady D, Cauley JA, Geiger MJ, Kornitzer M, Mosca L, Collins P, et al. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. Journal of the National Cancer Institute 2008;100(12):854‐61. - PMC - PubMed
Hercberg 2004 {published data only}
    1. Hercberg S, Galan P, Preziosi P, Bertrais S, Mennen L, Malvy D, et al. The SU.VI.MAX Study: a randomized, placebo‐controlled trial of the health effects of antioxidant vitamins and minerals. Archives of Internal Medicine 2004;164(21):2335‐42. - PubMed
Home 2009 {published data only}
    1. Home PD, Pocock SJ, Beck‐Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open‐label trial. Lancet 2009;373(9681):2125‐35. - PubMed
Home 2010 {published data only}
    1. Home PD, Kahn SE, Jones NP, Noronha D, Beck‐Nielsen H, Viberti G. Experience of malignancies with oral glucose‐lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010;53(9):1838‐45. - PMC - PubMed
HPSCG 2002 {published data only}
    1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high‐risk individuals: a randomised placebo‐controlled trial. Lancet 2002;360(9326):7‐22. - PubMed
Hue 2014 {published data only}
    1. Hue TF, Cummings SR, Cauley JA, Bauer DC, Ensrud KE, Barrett‐Connor E, et al. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Internal Medicine 2014;174(10):1550‐7. - PMC - PubMed
LaCroix 2010 {published data only}
    1. LaCroix AZ, Powles T, Osborne CK, Wolter K, Thompson DD, Allred DC, et al. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. Journal of the National Cancer Institute 2010;102(22):1706‐15. - PubMed
Lappe 2007 {published data only}
    1. Lappe JM, Travers‐Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. American Journal of Clinical Nutrition 2007;85(6):1586‐91. - PubMed
Lee 1999 {published data only}
    1. Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. Beta‐carotene supplementation and incidence of cancer and cardiovascular disease: the Women’s Health Study. Journal of the National Cancer Institute 1999;91(24):2102‐6. - PubMed
Lee 2005 {published data only}
    1. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trial. JAMA 2005;294(1):56‐65. - PubMed
LIPID 1998 {published data only}
    1. LIPID Investigators. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long‐Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. New England Journal of Medicine 1998;339:1349‐57. - PubMed
López 2016 {published data only}
    1. López AM, Pruthi S, Boughey JC, Perloff M, Hsu CH, Lang JE, et al. Double‐blind, randomized trial of alternative letrozole dosing regimens in postmenopausal women with increased breast cancer risk. Cancer Prevention Research 2016;9(2):142‐8. - PMC - PubMed
Martino 2004 {published data only}
    1. Martino S, Cauley JA, Barrett‐Connor E, Powles TJ, Mershon J, Disch D, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. Journal of the National Cancer Institute 2004;96(23):1751‐61. - PubMed
Powles 2012 {published data only}
    1. Powles TJ, Diem SJ, Fabian CJ, Neven P, Wickerham DL, Cox DA, et al. Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. Breast Cancer Research and Treatment 2012;134(1):299‐306. - PubMed
Prentice 2013 {published data only}
    1. Prentice RL, Pettinger MB, Jackson RD, Wactawski‐Wende J, Lacroix AZ, Anderson GL, et al. Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporosis International 2013;24(2):567‐80. - PMC - PubMed
Sacks 1996 {published data only}
    1. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine 1996;335(14):1001‐9. - PubMed
Shepherd 2002 {published data only}
    1. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360(9346):1623‐30. - PubMed
Strandberg 2004 {published data only}
    1. Strandberg TE, Pyorala K, Cook TJ. Mortality and incidence of cancer during 10‐year follow‐up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004;364(9436):771‐7. - PubMed
Trivedi 2003 {published data only}
    1. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326(7387):469. - PMC - PubMed
Veronesi 2007 {published data only}
    1. Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. Journal of the National Cancer Institute 2007;99(9):727‐37. - PubMed
Vogel 2006 {published data only}
    1. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P‐2 trial. JAMA 2006;295(23):2727‐41. - PubMed

Additional references

Advani 2014
    1. Advani P, Moreno‐Aspitia A. Current strategies for the prevention of breast cancer. Breast Cancer 2014;6:59‐71. - PMC - PubMed
Ahern 2014
    1. Ahern TP, Lash TL, Damkier P, Christiansen PM, Cronin‐Fenton DP. Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncology 2014;15(10):e461‐8. - PMC - PubMed
Alés‐Martínez 2015
    1. Alés‐Martínez JE, Ruiz A, Chacón JI, Lluch Hernández A, Ramos M, Córdoba O, et al. Preventive treatments for breast cancer: recent developments. Clinical & Translational Oncology 2015;17(4):257‐63. - PMC - PubMed
Behan 2015
    1. Behan LA, Amir E, Casper RF. Aromatase inhibitors for prevention of breast cancer in postmenopausal women: a narrative review. Menopause 2015;22(3):342‐50. - PubMed
Bosetti 2012
    1. Bosetti C, Rosato V, Gallus S, Cuzick J, Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Annals of Oncology 2012;23(6):1403‐15. - PubMed
Bucher 1997
    1. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta‐analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683‐91. - PubMed
Caldwell 2014
    1. Caldwell DM. An overview of conducting systematic reviews with network meta‐analysis. Systematic Reviews 2014;3:109. - PMC - PubMed
Campagnoli 2013
    1. Campagnoli C, Pasanisi P, Castellano I, Abbà C, Brucato T, Berrino F. Postmenopausal breast cancer, androgens, and aromatase inhibitors. Breast Cancer Research and Treatment 2013;139(1):1‐11. - PubMed
Carlson 2009
    1. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. Breast cancer. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network 2009;7(2):122‐92. - PubMed
Chaimani 2013
    1. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta‐analysis in STATA. PloS One 2013;8:e76654. - PMC - PubMed
Chlebowski 2002
    1. Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG 3rd, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. Journal of Clinical Oncology 2002;20(15):3328‐43. - PubMed
Chlebowski 2012
    1. Chlebowski RT, Col N. Bisphosphonates and breast cancer prevention. Anti‐Cancer Agents in Medicinal Chemistry 2012;12(2):144‐50. - PubMed
Chlebowski 2014
    1. Chlebowski RT. Current concepts in breast cancer chemoprevention. Polskie Archiwum Medycyny Wewnetrznej 2014;124(4):191‐9. - PubMed
Chumsri 2015
    1. Chumsri S. Clinical utilities of aromatase inhibitors in breast cancer. International Journal of Women's Health 2015;7:493‐9. - PMC - PubMed
Cipriani 2013
    1. Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta‐analysis. Annals of Internal Medicine 2013;159(2):130‐7. - PubMed
Colditz 2014
    1. Colditz GA, Bohlke K. Priorities for the primary prevention of breast cancer. CA: A Cancer Journal for Clinicians 2014;64(3):186‐94. - PubMed
Crew 2015
    1. Crew KD. Addressing barriers to uptake of breast cancer chemoprevention for patients and providers. American Society of Clinical Oncology Education Book 2015;35:e50‐8. - PMC - PubMed
Cummings 2009
    1. Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. Journal of the National Cancer Institute 2009;101:384‐98. - PMC - PubMed
Cuzick 2011
    1. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncology 2011;12(5):496‐503. - PubMed
Cuzick 2013
    1. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta‐analysis of individual participant data. Lancet 2013;381(9880):1827‐34. - PMC - PubMed
De la Cruz 2014
    1. Cruz MS, Sarfaty M, Wender RC. An update on breast cancer screening and prevention. Primary Care 2014;41(2):283‐306. - PubMed
Den Hollander 2013
    1. Hollander P, Savage MI, Brown PH. Targeted therapy for breast cancer prevention. Frontiers in Oncology 2013;3(250):1‐15. - PMC - PubMed
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88. - PubMed
Donnelly 2014
    1. Donnelly LS, Evans DG, Wiseman J, Fox J, Greenhalgh R, Affen J, et al. Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high‐risk breast cancer clinic. British Journal of Cancer 2014;110(7):1681‐7. - PMC - PubMed
Euhus 2015
    1. Euhus DM, Diaz J. Breast cancer prevention. Breast Journal 2015;21(1):76‐81. - PubMed
Feldman 2014
    1. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nature Reviews Cancer 2014;14(5):342‐57. - PubMed
Freedman 2015
    1. Freedman OC, Fletcher GG, Gandhi S, Mates M, Dent SF, Trudeau ME, et al. Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Current Oncology 2015;22(Suppl 1):S95‐113. - PMC - PubMed
Fuller 2015
    1. Fuller MS, Lee CI, Elmore JG. Breast cancer screening: an evidence‐based update. Medical Clinics of North America 2015;99(3):451‐68. - PMC - PubMed
Gabriel 2012
    1. Gabriel EM, Jatoi I. Breast cancer chemoprevention. Expert Review of Anticancer Therapy 2012;12(2):223‐8. - PubMed
Gail 2015
    1. Gail MH. Twenty‐five years of breast cancer risk models and their applications. Journal of the National Cancer Institute 2015;107(5):pii: djv042. - PMC - PubMed
Gandini 2014
    1. Gandini S, Puntoni M, Heckman‐Stoddard BM, Dunn BK, Ford L, DeCensi A, et al. Metformin and cancer risk and mortality: a systematic review and meta‐analysis taking into account biases and confounders. Cancer Prevention Research 2014;7(9):867‐85. - PMC - PubMed
Giammanco 2015
    1. Giammanco M, Majo D, Guardia M, Aiello S, Crescimannno M, Flandina C, et al. Vitamin D in cancer chemoprevention. Pharmaceutical Biology 2015;53(10):1399‐434. - PubMed
Gonçalves 2014
    1. Gonçalves AK, Dantas Florencio GL, Maisonnette de Atayde Silva MJ, Cobucci RN, Giraldo PC, Cote NM. Effects of physical activity on breast cancer prevention: a systematic review. Journal of Physical Activity & Health 2014;11(2):445‐54. - PubMed
Gradishar 2015
    1. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. Breast cancer version 2.2015. Journal of the National Comprehensive Cancer Network 2015;13(4):448‐75. - PubMed
Gronich 2013
    1. Gronich N, Rennert G. Beyond aspirin‐cancer prevention with statins, metformin and bisphosphonates. Nature Reviews Clinical Oncology 2013;10(11):625‐42. - PubMed
Guyatt 2011
    1. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology 2011;64(4):380‐2. - PubMed
Heemskerk‐Gerritsen 2015
    1. Heemskerk‐Gerritsen BA, Seynaeve C, Asperen CJ, Ausems MG, Collée JM, Doorn HC, et al. Breast cancer risk after salpingo‐oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. Journal of the National Cancer Institute 2015;107(5):pii: djv033. - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins 2012
    1. Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta‐analysis: concepts and models for multi‐arm studies. Research Synthesis Methods 2012;3(2):98‐110. - PMC - PubMed
Holmberg 2015
    1. Holmberg C. Decision making in the context of breast cancer chemoprevention: patient perceptions and the meaning of risk. American Society of Clinical Oncology Educational Book 2015;35:e59‐64. - PubMed
Howell 2014
    1. Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia‐Closas M, et al. Risk determination and prevention of breast cancer. Breast Cancer Research 2014;16(5):446. - PMC - PubMed
Jacobo‐Herrera 2014
    1. Jacobo‐Herrera NJ, Pérez‐Plasencia C, Camacho‐Zavala E, González GF, Urrutia EL, García‐Castillo V, et al. Clinical evidence of the relationship between aspirin and breast cancer risk (review). Oncology Reports 2014;32(2):451‐61. - PubMed
Kotsopoulos 2016
    1. Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, et al. Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute 2016;109(1):pii: djw177. - PMC - PubMed
Landis‐Piwowar 2014
    1. Landis‐Piwowar KR, Iyer NR. Cancer chemoprevention: current state of the art. Cancer Growth Metastasis 2014;7:19‐25. - PMC - PubMed
Layeequr 2009
    1. Layeequr Rahman R, Crawford S. Chemoprevention Indication Score: a user‐friendly tool for prevention of breast cancer – pilot analysis. Breast 2009;18(5):289‐93. - PubMed
Lazzeroni 2011
    1. Lazzeroni M, Gandini S, Puntoni M, Bonanni B, Gennari A, DeCensi A. The science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it. Breast 2011;20(Suppl 3):S36‐41. - PubMed
Lazzeroni 2013
    1. Lazzeroni M, DeCensi A. Breast cancer prevention by antihormones and other drugs: where do we stand?. Hematology/Oncology Clinics of North America 2013;27(4):657‐72. - PubMed
Lebovic 2010
    1. Lebovic GS, Hollingsworth A, Feig SA. Risk assessment, screening and prevention of breast cancer: a look at cost‐effectiveness. Breast 2010;19(4):260‐7. - PubMed
Litton 2012
    1. Litton JK, Arun BK, Brown PH, Hortobagyi GN. Aromatase inhibitors and breast cancer prevention. Expert Opinion on Pharmacotherapy 2012;13(3):325‐31. - PubMed
Liu 2012
    1. Liu Y, Zhao S, Chen W, Hu F, Zhu L, Zhang Q, et al. Bisphosphonate use and the risk of breast cancer: a meta‐analysis of published literature. Clinical Breast Cancer 2012;12(4):276‐81. - PubMed
Lostumbo 2010
    1. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database of Systematic Reviews 2010, Issue 10. [DOI: 10.1002/14651858.CD002748.pub3] - DOI - PubMed
Mirkin 2015
    1. Mirkin S, Pickar JH. Selective estrogen receptor modulators (SERMs): a review of clinical data. Maturitas 2015;80(1):52‐7. - PubMed
Mocellin 2015
    1. Mocellin S, Pilati P, Briarava M, Nitti D. Breast cancer chemoprevention: a network meta‐analysis of randomized controlled trials. Journal of the National Cancer Institute 2015;108(2):pii: djv318. - PubMed
Moyer 2013
    1. Moyer VA, U.S. Preventive Services Task Force. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine 2013;159(10):698‐708. - PubMed
Nazarali 2014
    1. Nazarali SA, Narod SA. Tamoxifen for women at high risk of breast cancer. Breast Cancer 2014;6:29‐36. - PMC - PubMed
Nelson 2013
    1. Nelson HD, Smith ME, Griffin JC, Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Annals of Internal Medicine 2013;158(8):604‐14. - PubMed
NICE 2017
    1. National Institute for health Care Excellence (NICE). Breast cancer risk category. https://www.nice.org.uk/guidance/cg164/chapter/recommendations#breast‐ca... 2017.
Nichols 2014
    1. Nichols HB, DeRoo LA, Scharf DR, Sandler DP. Risk‐benefit profiles of women using tamoxifen for chemoprevention. Journal of the National Cancer Institute 2014;107(1):354. - PMC - PubMed
Olin 2014
    1. Olin JL, Pierre M. Aromatase inhibitors in breast cancer prevention. Annals of Pharmacotherapy 2014;48(12):1605‐10. - PubMed
Onega 2014
    1. Onega T, Beaber EF, Sprague BL, Barlow WE, Haas JS, Tosteson AN, et al. Breast cancer screening in an era of personalized regimens: a conceptual model and National Cancer Institute initiative for risk‐based and preference‐based approaches at a population level. Cancer 2014;120(19):2955‐64. - PMC - PubMed
Pace 2014
    1. Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast cancer screening decisions. JAMA 2014;311(13):1327‐35. - PubMed
Review Manager 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rhodes 2015
    1. Rhodes KM, Turner RM, Higgins JP. Predictive distributions were developed for the extent of heterogeneity in meta‐analyses of continuous outcome data. Journal of Clinical Epidemiology 2015;68(1):52‐60. - PMC - PubMed
Romagnolo 2014
    1. Romagnolo AP, Romagnolo DF, Selmin OI. BRCA1 as target for breast cancer prevention and therapy. Anti‐Cancer Agents in Medicinal Chemistry 2014;15(1):4‐14. - PubMed
Ropka 2010
    1. Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta‐analysis. Journal of Clinical Oncology 2010;28(18):3090‐5. - PMC - PubMed
Rossi 2014
    1. Rossi RE, Pericleous M, Mandair D, Whyand T, Caplin ME. The role of dietary factors in prevention and progression of breast cancer. Anticancer Research 2014;34(12):6861‐75. - PubMed
Rothwell 2012
    1. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012;379(9826):1591‐601. - PubMed
Salanti 2008
    1. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Statistical Methods in Medical Research 2008;17(3):279‐301. - PubMed
Salanti 2011
    1. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple‐treatment meta‐analysis: an overview and tutorial. Journal of Clinical Epidemiology 2011;64(2):163‐71. - PubMed
Salanti 2014
    1. Salanti G, Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta‐analysis. Plos One 2014;9(7):e99682. - PMC - PubMed
Santa‐Maria 2013
    1. Santa‐Maria CA, Stearns V. Statins and breast cancer: future directions in chemoprevention. Current Breast Cancer Reports 2013;5(3):161‐9. - PMC - PubMed
Schiavon 2013
    1. Schiavon G, Smith IE. Endocrine therapy for advanced/metastatic breast cancer. Hematology/Oncology Clinics of North America 2013;27(4):715‐36. - PubMed
Serrano 2015
    1. Serrano D, Lazzeroni M, Bonanni B. Cancer chemoprevention: much has been done, but there is still much to do. State of the art and possible new approaches. Molecular Oncology 2015;9(5):1008‐17. - PMC - PubMed
Sestak 2015
    1. Sestak I, Cuzick J. Update on breast cancer risk prediction and prevention. Current Opinion in Obstetrics & Gynecology 2015;27(1):92‐7. - PubMed
Smith 2016
    1. Smith SG, Sestak I, Forster A, Partridge A, Side L, Wolf MS, et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta‐analysis. Annals of Oncology 2016;27(4):575‐90. - PMC - PubMed
Sostres 2014
    1. Sostres C, Gargallo CJ, Lanas A. Aspirin, cyclooxygenase inhibition and colorectal cancer. World Journal of Gastrointestinal Pharmacology and Therapeutics 2014;5(1):40‐9. - PMC - PubMed
StataCorp 2009 [Computer program]
    1. StataCorp LP. Stata Statistical Software. Version Release 11. College Station (TX): StataCorp LP, 2009.
Stine 2014
    1. Stine JE, Bae‐Jump V. Metformin and gynecologic cancers. Obstetrics & Gynecological Survey 2014;69(8):477‐89. - PubMed
Stout 2014
    1. Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, et al. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. Journal of the National Cancer Institute 2014;106(6):dju092. - PMC - PubMed
Stubert 2014
    1. Stubert J, Dieterich M, Gerber B. Medical prevention of breast cancer. Breast Care 2014;9(6):391‐6. - PMC - PubMed
Thorat 2013
    1. Thorat MA, Cuzick J. Role of aspirin in cancer prevention. Current Oncology Reports 2013;15(6):533‐40. - PubMed
Torre 2015
    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2015;65(2):87‐108. - PubMed
Turner 2012
    1. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta‐analysis, using empirical data from the Cochrane Database of Systematic Reviews. International Journal of Epidemiology 2012;41(3):818‐27. - PMC - PubMed
Tuttle 2010
    1. Tuttle TM, Abbott A, Arrington A, Rueth N. The increasing use of prophylactic mastectomy in the prevention of breast cancer. Current Oncology Reports 2010;12(1):16‐21. - PubMed
Veroniki 2013
    1. Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. International Journal of Epidemiology 2013;42(1):332‐45. - PMC - PubMed
Visvanathan 2013
    1. Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology 2013;31(23):2942‐62. - PubMed
Vogel 2015
    1. Vogel VG. Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction. BMC Medicine 2015;13:63. - PMC - PubMed
Wang 2015
    1. Wang W, Nag SA, Zhang R. Targeting the NFκB signaling pathways for breast cancer prevention and therapy. Current Medicinal Chemistry 2015;22(2):264‐89. - PMC - PubMed
White 2011
    1. White IR. Multivariate random‐effects meta‐regression: updates to mvmeta. Stata Journal 2011;11(2):255‐70.
White 2012
    1. White IR, Barrett JK, Jackson D, Higgins JPT. Consistency and inconsistency in network meta‐analysis: model estimation using multivariate meta‐regression. Research Synthesis Methods 2012;3(2):111‐25. - PMC - PubMed
Williams 2014
    1. Williams N, Harris LN. The renaissance of endocrine therapy in breast cancer. Current Opinion in Obstetrics & Gynecology 2014;26(1):41‐7. - PubMed
Wuttke 2015
    1. Wuttke M, Phillips KA. Clinical management of women at high risk of breast cancer. Current Opinion in Obstetrics & Gynecology 2015;27(1):6‐13. - PubMed
Yeo 2014
    1. Yeo B, Turner NC, Jones A. An update on the medical management of breast cancer. BMJ 2014;348:g3608. - PubMed

References to other published versions of this review

Mocellin 2016
    1. Mocellin S, Goodwin A, Pasquali S. Risk‐reducing medication for primary breast cancer: a network meta‐analysis. Cochrane Database of Systematic Reviews 2016, Issue 5. [DOI: 10.1002/14651858.CD012191] - DOI - PMC - PubMed

Publication types

MeSH terms

Substances